Pembrolizumab

Grey

Brand Name(s):KEYTRUDA

Indication:Locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy

Rationale:1

Considered:Aug-15

Review Date:May-26

Comments:
NICE TA692
Pembrolizumab is not recommended for locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. The most plausible cost effectiveness estimate were higher than what NICE normally considers acceptable for end of life treatments. April 2021

NICE TA683 recommend pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no EGFR or ALK +ve mutations, only if it is stopped at 2 years of uninterrupted treatment, or earlier.
March ’21.

NICE TA661 Recommends pembrolizumab for untreated metastatitic/unresectable recurrent head and neck squamous cell carcinoma in adults with PD-L1+ve tumours.
NICE TA650 does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults. Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA428
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
January 2017